Published in Am J Cardiol on May 15, 1999
Activating peripheral arterial disease patients to reduce cholesterol: a randomized trial. Am J Med (2011) 1.50
Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther (2008) 1.08
High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. Vasc Health Risk Manag (2008) 0.97
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res (2016) 0.88
Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia. J Natl Med Assoc (2006) 0.84
Twenty questions on atherosclerosis. Proc (Bayl Univ Med Cent) (2000) 0.84
Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. Exp Clin Cardiol (2007) 0.76
Statins, high-density lipoprotein, and the low-density lipoprotein/high-density lipoprotein ratio. Am J Cardiol (2000) 0.75
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet (1999) 7.30
The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med (1993) 4.61
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA (1996) 4.03
The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem (2001) 2.71
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation (2001) 2.41
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation (1998) 2.40
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet (2003) 2.37
[Finnish descendants in the municipality of Sor-Varanger--II. An investigation of blood pressure, height, weight, cholesterol, triglycerides and lipoproteins among Finnish descendant men--and the effect of a diet change]. Tidsskr Nor Laegeforen (1974) 2.33
The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res (1997) 2.14
Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet (2001) 2.08
The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol (1994) 2.04
Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest (2000) 1.98
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Cancer genetics clinics: target population and consultees' expectations. Eur J Cancer (1996) 1.88
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf (1996) 1.85
Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol (1998) 1.80
A heritable syndrome of craniosynostosis, short thin hair, dental abnormalities, and short limbs: cranioectodermal dysplasia. J Pediatr (1977) 1.71
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med (1996) 1.68
Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2008) 1.67
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol (1999) 1.62
DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias. Am J Hum Genet (1987) 1.61
Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br (2002) 1.58
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol (1997) 1.56
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. J Clin Invest (1982) 1.54
Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects. Eur J Clin Invest (1998) 1.48
Homozygous Tangier disease and cardiovascular disease. Atherosclerosis (1994) 1.48
Early sexual debut among young men in rural South Africa: heightened vulnerability to sexual risk? Sex Transm Infect (2005) 1.47
Parosteal osteosarcoma dedifferentiating into telangiectatic osteosarcoma: importance of lytic changes and fluid cavities at imaging. Skeletal Radiol (2009) 1.47
Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr (1996) 1.47
Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol (2009) 1.44
Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution. Int Orthop (2006) 1.43
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol (2011) 1.40
Serum lactate dehydrogenase glutamic oxaloacetic transaminase ratio and liver metastases. Can Med Assoc J (1981) 1.40
The human carotid atherosclerotic plaque stimulates angiogenesis on the chick chorioallantoic membrane. Atherosclerosis (1992) 1.39
Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer (2001) 1.34
Fluid endocytosis in isolated rat parenchymal and non-parenchymal liver cells. Exp Cell Res (1980) 1.33
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol (1998) 1.32
Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res (2001) 1.29
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol (2000) 1.27
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol (2010) 1.25
Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol (2001) 1.25
Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer (1999) 1.24
Decreased anion gap associated with monoclonal and pseudomonoclonal gammopathy. Can Med Assoc J (1976) 1.21
Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb (1991) 1.21
Leukocyte count correlates in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol (1992) 1.21
Associations of risk factors with segment-specific intimal-medial thickness of the extracranial carotid artery. Stroke (1999) 1.20
Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol (1993) 1.19
Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol (1996) 1.19
Osteosarcoma. Low-grade intraosseous-type osteosarcoma, histologically resembling parosteal osteosarcoma, fibrous dysplasia, and desmoplastic fibroma. Cancer (1993) 1.18
Autosomal dominant partial lipodystrophy associated with Rieger anomaly, short stature, and insulinopenic diabetes. Am J Med Genet (1983) 1.18
Surgical treatment and outcome of conventional pelvic chondrosarcoma. J Bone Joint Surg Br (2005) 1.16
The effects of age, smoking, and alcohol on routine laboratory tests. Am J Clin Pathol (1981) 1.16
Physicians' response to abnormal results of routine urinalysis. Can Med Assoc J (1976) 1.16
Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand (1998) 1.16
Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol (1997) 1.16
Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study. Eur J Clin Pharmacol (1991) 1.16
Massive bone allograft reconstruction in high-grade osteosarcoma. Clin Orthop Relat Res (2000) 1.13
Functional modeling of vitamin responsiveness in yeast: a common pyridoxine-responsive cystathionine beta-synthase mutation in homocystinuria. Hum Mol Genet (1997) 1.13
Modular prosthetic replacement of the proximal femur after resection of a bone tumour a long-term follow-up. J Bone Joint Surg Br (2001) 1.13
New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation (1987) 1.13
Apolipoprotein(a), fibrinopeptide A and carotid atherosclerosis in middle-aged men. Thromb Haemost (1994) 1.12
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am J Cardiol (2000) 1.10
Position statement of the CSCC and CAP Task Force on the measurement of lipids for the assessment of risk of CHD. Clin Biochem (1989) 1.10
Fine mapping of a gene responsible for regulating dietary cholesterol absorption; founder effects underlie cases of phytosterolaemia in multiple communities. Eur J Hum Genet (2001) 1.07
High AIDS-related mortality among young women in rural KwaZulu-Natal. S Afr Med J (2007) 1.06
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost (2013) 1.05
Neonatal screening for hyperlipidaemia. Postgrad Med J (1975) 1.05
Osteoarticular allograft reconstruction of the distal radius after bone tumour resection. J Hand Surg Br (2005) 1.04
Genetic contributions to generalized arousal of brain and behavior. Proc Natl Acad Sci U S A (2003) 1.04
A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther (1994) 1.04
Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol (1997) 1.04
High frequency of mutations in the human lipoprotein lipase gene in pregnancy-induced chylomicronemia: possible association with apolipoprotein E2 isoform. J Lipid Res (1994) 1.02
Radiological features of 24 periosteal chondrosarcomas. Skeletal Radiol (2001) 1.02
Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke (1996) 1.02
Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study. Acta Oncol (1998) 1.01
Osteosarcoma of the pelvis. Eur J Surg Oncol (2004) 1.01
Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172-->Cys mutation in the lipoprotein lipase gene. J Clin Invest (1993) 1.00
Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis (1982) 1.00
Ablation of bone cells by electroporation. J Bone Joint Surg Br (2010) 0.99
Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol (1996) 0.98
Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial. CMAJ (2001) 0.98
Reproducibility and validity of a short food questionnaire for the assessment of dietary habits. Nutr Metab Cardiovasc Dis (2002) 0.97
Phytosterolaemia in a Norwegian family: diagnosis and characterization of the first Scandinavian case. Scand J Clin Lab Invest (1996) 0.97
Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute. Eur J Cancer (2002) 0.97
Effect of fasting on free and esterified carnitine levels in human serum and urine: correlation with serum levels of free fatty acids and beta-hydroxybutyrate. Metabolism (1978) 0.97
Hypoalphalipoproteinemia resembling fish eye disease. Acta Med Scand (1987) 0.97
A prospective study of 18 patients with cholestasis of pregnancy. Am J Obstet Gynecol (1982) 0.96
Ankle resection arthrodesis in patients with bone tumors. Foot Ankle Int (1994) 0.96
Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol (2001) 0.96
Allograft arthrodesis treatment of bone tumors: a two-center study. Clin Orthop Relat Res (2002) 0.96
Vascular homografts for vessel substitution in skeletal and soft tissue sarcomas of the limbs. Transplant Proc (2005) 0.95
Effects of the phytoestrogen coumestrol on locomotor and fear-related behaviors in female mice. Horm Behav (2001) 0.94
Osteoid osteoma and osteoblastoma of the sacrum. Orthopedics (2001) 0.94
Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B. Kidney Int (2001) 0.94